Skip to main content
SpringerLink
Log in

Osteogenesis Imperfecta

Practical Treatment Guidelines

  • Review Article
  • Published:
Paediatric Drugs Aims and scope Submit manuscript

Abstract

Osteogenesis imperfecta (OI), an inherited connective tissue disorder of remarkable clinical variability, is caused by a quantitative or qualitative defect in collagen synthesis and is characterised by bone fragility. The number of fractures and deformities, and the age at which they begin greatly influence the prognosis and the achievement of walking and autonomy.

A multidisciplinary team approach is essential for diagnosis, for communication with patient and parents, and to tailor treatment needs to the severity of the disease and the age of the patient.

Three types of treatment are available: nonsurgical management (physical therapy, rehabilitation, bracing and splinting), surgery (intramedullary rod positioning, spinal and basilar impression surgery), and drugs to increase the strength of bone and decrease the number of fractures.

An aggressive rehabilitative approach is indicated to optimise functional ability and walking capacity; appropriately timed surgery to insert intramedullary rods provides improved function of extremities. Despite a high rate of complications, intramedullary telescopic roding has proven to be the most successful method for preventing and correcting fractures and deformities of long bones, improving walking capability and leading to successful rehabilitation of even severely affected patients. Surgery may be required in patients with progressive spinal deformity and in those with symptomatic basilar impression. Hearing function, dentinogenesis imperfecta, cardiac and respiratory function, and neurological changes must be monitored.

The causal defect of the disease cannot be corrected with medical treatment and, currently, only symptomatic therapy is available. In recent years growth hormone (GH) and bisphosphonate agents have been used in OI therapy. GH is beneficial in patients with moderate forms of OI, showing a positive effect on bone turnover, bone mineral density and height velocity rate. Bisphosphonates have proved beneficial in children with severe OI, increasing bone mineral density and reducing the fracture rate and pain with no adverse effects reported. These data require confirmation in double-blind controlled studies; however, bisphosphonates have markedly improved morbidity in patients with OI.

Future developments in genetic therapy may be directed towards either replacing cells carrying the mutant gene with normal cells or silencing the mutant allele using antisense suppression therapy, thus transforming a biochemically severe form of OI into a mild form.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Byers PH. Osteogenesis imperfecta. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders: molecular, genetic and medical aspects. New York: Wiley-Liss Inc, 1993: 317–50

    Google Scholar 

  2. Smith R, Francis MJO, Houghton GR. The brittle bone syndrome: osteogenesis imperfecta. London: Butterworths, 1983

    Google Scholar 

  3. Dalgleish R. The human type I collagen mutation database. Nucleic Acids Res 1997 Jan 1; 25(1): 181–7

    Article  PubMed  CAS  Google Scholar 

  4. Cole WG. The Nicholas Andry Award-1996. The molecular pathology of osteogenesis imperfecta. Clin Orthop 1997; 343: 235–48

    PubMed  Google Scholar 

  5. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101–16

    Article  PubMed  CAS  Google Scholar 

  6. Shapiro F. Consequences of an osteogenesis imperfecta diagnosis for survival and ambulation. J Pediatr Orthop 1985; 5: 456–62

    Article  PubMed  CAS  Google Scholar 

  7. Willing MC, Deschenes SP, Scott DA, et al. Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Hum Genet 1994; 55: 638–47

    PubMed  CAS  Google Scholar 

  8. Lund AM, Muller J, Skovby F. Anthropometry of patients with osteogenesis imperfecta. Arch Dis Child 1999; 80: 524–8

    Article  PubMed  CAS  Google Scholar 

  9. Garretsen AJ, Cremers CW, Huygen PL. Hearing loss (in non-operated ears) in relation to age in osteogenesis imperfecta type I. Ann Otol Rhinol Laryngol 1997; 106: 575–82

    PubMed  CAS  Google Scholar 

  10. Hortop J, Tsipouras P, Hanley JA, et al. Cardiovascular involvement in osteogenesis imperfecta. Circulation 1986; 73: 54–61

    Article  PubMed  CAS  Google Scholar 

  11. Cohn DH, Starman BJ, Blumberg B, et al. Recurrence of lethal osteogenesis imperfecta due to parental mosaicism for a dominant mutation in a human type I collagen gene (COL1A1). Am J Hum Genet 1990; 46: 591–601

    PubMed  CAS  Google Scholar 

  12. Byers PH, Tsipouras P, Bonadio JF, et al. Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen. Am J Hum Genet 1988; 42: 237–48

    PubMed  CAS  Google Scholar 

  13. Lund AM, Nicholls AC, Schwartz M, et al. Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/TV. Acta Paediatr 1997; 86: 711–8

    Article  PubMed  CAS  Google Scholar 

  14. Engelbert RH, Gerver WJ, Breslau-Siderius LJ, et al. Spinal complications in osteogenesis imperfecta: 47 patients 1–16 years of age. Acta Orthop Scand 1998; 69: 283–6

    Article  PubMed  CAS  Google Scholar 

  15. Charnas LR, Marini JC. Communicating hydrocephalus, basilar invagination, and other neurological features in osteogenesis imperfecta. Neurology 1993; 43: 2603–8

    Article  PubMed  CAS  Google Scholar 

  16. Sawin PD, Menezes AH. Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management. J Neurosurg 1997; 86: 950–60

    Article  PubMed  CAS  Google Scholar 

  17. O’Connell AC, Marini JC. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 189–96

    Article  PubMed  Google Scholar 

  18. Antoniazzi F, Sirpresi S, Brunelli PC, et al. The multidisciplinary experience for the study of osteogenesis imperfecta in Italy. Sixth International Conference on Osteogenesis Imperfecta. 1996 Sep 19–21; Utrecht, The Netherlands

  19. Chapman S, Hall CM. Non-accidental injury or brittle bones. Pediatr Radiol 1997; 27: 106–10

    Article  PubMed  CAS  Google Scholar 

  20. Ablin DS, Sane SM. Non-accidental injury: confusion with temporary brittle bone disease and mild osteogenesis imperfecta. Pediatr Radiol 1997; 27: 111–3

    Article  PubMed  CAS  Google Scholar 

  21. Miller ME, Hangartner TN. Temporary brittle bone disease: association with decreased fetal movement and osteopenia. Calcif Tissue Int 1999; 64: 137–43

    Article  PubMed  CAS  Google Scholar 

  22. Smith R. Osteogenesis imperfecta, non-accidental injury, and temporary brittle bone disease. Arch Dis Child 1995; 72: 169–71

    Article  PubMed  CAS  Google Scholar 

  23. Moore MS, Minch CM, Kruse RW, et al. The role of dual energy x-ray absorptiometry in aiding the diagnosis of pediatric osteogenesis imperfecta. Am J Orthop 1998; 27: 797–801

    PubMed  CAS  Google Scholar 

  24. Zionts LE, Nash JP, Rude R, et al. Bone mineral density in children with mild osteogenesis imperfecta. J Bone Joint Surg Br 1995; 77: 143–7

    PubMed  CAS  Google Scholar 

  25. Davie MWJ, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child 1994; 70: 331–4

    Article  PubMed  CAS  Google Scholar 

  26. Lund AM, Hansen M, Kollerup G, et al. Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr 1998; 87: 1131–7

    Article  PubMed  CAS  Google Scholar 

  27. Cassella JP, Stamp TC, Ali SY. A morphological and ultrastructural study of bone in osteogenesis imperfecta. Calcif Tissue Int 1996; 58: 155–65

    PubMed  CAS  Google Scholar 

  28. Jones SJ, Glorieux FH, Travers R, et al. The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging. Calcif Tissue Int 1999; 64: 8–17

    Article  PubMed  CAS  Google Scholar 

  29. Steiner RD, Pepin M, Byers PH. Studies of collagen synthesis and structure in the differentiation of child abuse from osteogenesis imperfecta. J Pediatr 1996; 128: 542–7

    Article  PubMed  CAS  Google Scholar 

  30. Baron R, Gertner JM, Lang R, et al. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983; 17: 204–7

    Article  PubMed  CAS  Google Scholar 

  31. Brenner RE, Vetter U, Bollen AM, et al. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Min Res 1994; 9: 993–7

    Article  CAS  Google Scholar 

  32. Castells S, Yasumura S, Fusi MA, et al. Plasma osteocalcin levels in patients with osteogenesis imperfecta. J Pediatr 1986; 109: 88–91

    Article  PubMed  CAS  Google Scholar 

  33. Brenner RE, Schiller B, Vetter U, et al. Serum concentrations of procollagen I C-terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr 1993; 82: 764–7

    Article  PubMed  CAS  Google Scholar 

  34. Rico H. Osteocalcin levels in patients with osteogenesis imperfecta. J Pediatr 1987; 111: 634

    PubMed  CAS  Google Scholar 

  35. Chines A, Boniface A, McAlister W, et al. Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects. Bone 1995; 16: 333–9

    Article  PubMed  CAS  Google Scholar 

  36. Constantine G, McCormack J, McHugo J, et al. Prenatal diagnosis of severe osteogenesis imperfecta. Prenat Diagn 1991; 11: 103–10

    Article  PubMed  CAS  Google Scholar 

  37. Mottes M, Sangalli A, Pignatti PF. Haplotype analysis of collagen type I genes in the general population and in osteogenesis imperfecta families. Am J Med Genet 1993; 45: 217–22

    Article  PubMed  CAS  Google Scholar 

  38. Pepin M, Atkinson M, Starman BJ, et al. Strategies and outcomes of prenatal diagnosis for osteogenesis imperfecta: a review of biochemical and molecular studies completed in 129 pregnancies. Prenat Diagn 1997; 17: 559–70

    Article  PubMed  CAS  Google Scholar 

  39. Cohen-Solal L, Zolezzi F, Pignatti PF, et al. Intrafamilial variable expressivity of osteogenesis imperfecta due to mosaicism for a lethal G382R substitution in the COL1A1 gene. Mol Cell Probes 1996; 10: 219–25

    Article  PubMed  CAS  Google Scholar 

  40. McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta. J Clin Path 1996; 49: 627–30

    Article  PubMed  CAS  Google Scholar 

  41. Daly K, Wisbeach A, Sanpera Jr I, et al. The prognosis for walking in osteogenesis imperfecta. J Bone Joint Surg Br 1996; 78: 477–80

    PubMed  CAS  Google Scholar 

  42. Cheng M, Cubert R, Mack S, et al. Osteogenesis imperfecta: pregnancy characteristics, mode of delivery, and neonatal outcome [abstract 0–23]. 7th International Conference on Osteogenesis Imperfecta. 1999 Aug 29–Sep 1; Montreal, Canada

  43. Engelbert RH, Pruijs HE, Beemer FA, et al. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 1998; 79: 1590–4

    Article  PubMed  CAS  Google Scholar 

  44. Russel DJ, Rosenbraun P, Gowland C, et al. Gross motor function measure manual 2nd ed. Hamilton (Ont): McMaster University, 1993

    Google Scholar 

  45. Msall ME, DiGaudio K, Duffy LC, et al. WeeFIM. Normative sample of an instrument for tracking functional independence in children. Clin Pediatr Phila 1994; 33: 431–8

    Article  PubMed  CAS  Google Scholar 

  46. Bleck EE. Non operative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orth Rel Res 1981; 159: 111–22

    Google Scholar 

  47. Binder H, Conway A, Gerber LH. Rehabilitation approaches to children with osteogenesis imperfecta: a ten-year experience. Arch Phys Med Rehabil 1993; 74: 386–90

    PubMed  CAS  Google Scholar 

  48. Brunelli PC, Frediani P. Surgical treatment of the deformities of the long bones in severe osteogenesis imperfecta. Ann NY Acad Sci 1988; 543: 170–9

    Article  PubMed  CAS  Google Scholar 

  49. Kocher MS, Shapiro F. Osteogenesis imperfecta. J Am Acad Orthop Surg 1998; 6: 225–36

    PubMed  CAS  Google Scholar 

  50. Gargan MF, Wisbeach A, Fixsen JA. Humeral roding in osteogenesis imperfecta. J Pediatr Orthop 1996; 16: 719–22

    Article  PubMed  CAS  Google Scholar 

  51. Peluso A, Cerullo M. Malignant hyperthermia susceptibility in patients with osteogenesis imperfecta. Paediatr Anaesth 1995; 5: 398–9

    Article  PubMed  CAS  Google Scholar 

  52. McHale KA, Tenuta JJ, Tosi LL, et al. Percutaneous intramedullary fixation of long bone deformity in severe osteogenesis imperfecta. Clin Orthop 1994; 305: 242–8

    PubMed  Google Scholar 

  53. Jerosch J, Mazzotti I, Tomasevic M. Complications after treatment of patients with osteogenesis imperfecta with a Bailey-Dubow rod. Arch Orthop Trauma Surg 1998; 117: 240–5

    Article  PubMed  CAS  Google Scholar 

  54. Zionts LE, Ebramzadeh E, Stott NS. Complications in the use of the Bailey-Dubow extensible nail. Clin Orthop 1998; 348: 186–95

    PubMed  Google Scholar 

  55. Nicholas RW, James P. Telescoping intramedullary stabilization of the lower extremities for severe osteogenesis imperfecta. J Pediatr Orthop 1990; 10: 219–23

    PubMed  CAS  Google Scholar 

  56. Luhmann SJ, Sheridan JJ, Capelli AM, et al. Management of lower-extremity deformities in osteogenesis imperfecta with extensible intramedullary rod technique: a 20-year experience. J Pediatr Orthop 1998; 18: 88–94

    PubMed  CAS  Google Scholar 

  57. Engelbert RH, Helders PJ, Keessen W, et al. Intramedullary roding in type III osteogenesis imperfecta. Effects on neuromotor development in 10 children. Acta Orthop Scand 1995; 66: 361–4

    Article  PubMed  CAS  Google Scholar 

  58. Gerber LH, Binder H, Berry R, et al. Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Arch Phys Med Rehabil 1998; 79: 46–51

    Article  PubMed  CAS  Google Scholar 

  59. Binder H, Conway A, Hason S, et al. Comprehensive rehabilitation of the child with osteogenesis imperfecta. Am J Med Genet 1993; 45: 265–9

    Article  PubMed  CAS  Google Scholar 

  60. Hanscom DA, Bloom BA. The spine in osteogenesis imperfecta. Orthop Clin North Am 1988; 19: 449–58

    PubMed  CAS  Google Scholar 

  61. Livesley PJ, Webb PJ. Spinal fusion in situ in osteogenesis imperfecta. Int Orthop 1996; 20: 43–6

    Article  PubMed  CAS  Google Scholar 

  62. Wang TG, Yang GF, Alba A. Chronic ventilator use in osteogenesis imperfecta congenita with basilar impression: a case report. Arch Phys Med Rehabil 1994; 75: 699–702

    Article  PubMed  CAS  Google Scholar 

  63. Smith R, Phillips AT. Osteoporosis during pregnancy and its management. Scand J Rheumatol 1998; 107 Suppl.: 66–7

    CAS  Google Scholar 

  64. Garretsen TJ, Cremers CW. Stapes surgery in osteogenesis imperfecta: analysis of postoperative hearing loss. Ann Otol Rhinol Laryngol 1991; 100: 120–30

    PubMed  CAS  Google Scholar 

  65. Szilvassy J, Jori J, Czigner J, et al. Cochlear implantation in osteogenesis imperfecta. Acta Otorhinolaryngol Belg 1998; 52: 253–6

    PubMed  CAS  Google Scholar 

  66. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–13

    Article  PubMed  CAS  Google Scholar 

  67. Albright JA. Systemic treatment of osteogenesis imperfecta. Clin Orthop 1981; 159: 88–96

    PubMed  Google Scholar 

  68. Pedersen U, Charles P, Hansen HH, et al. Lack of effects of human calcitonin in osteogenesis imperfecta. Acta Orthop Scand 1985; 56: 260–4

    Article  PubMed  CAS  Google Scholar 

  69. Chevrel G, Meunier PJ. Are drugs helpful in adults with osteogenesis imperfecta? Rev Rhum Engl Ed 1997; 64: 283–6

    PubMed  CAS  Google Scholar 

  70. Ohlsson C, Bengtsson B, Isaksson OGP, et al. Growth hormone and bone. Endocrinol Rev 1998; 19: 55–79

    Article  CAS  Google Scholar 

  71. Ernst M, Rodan GA. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3. Endocrinology 1990; 127: 807–14

    Article  PubMed  CAS  Google Scholar 

  72. McCarthy TL, Centrella M, Canalis E. Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 1989; 124: 301–9

    Article  PubMed  CAS  Google Scholar 

  73. Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 1988; 122: 254–60

    Article  PubMed  CAS  Google Scholar 

  74. Wergedal JE, Mohan S, Lundy M, et al. Skeletal growth factor and other factors known to be present in bone matrix stimulate proliferation and protein synthesis in human bone cells. J Bone Mineral Res 1990; 5: 179–86

    Article  CAS  Google Scholar 

  75. Marini JC, Bordenick S, Heavner G, et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 1993; 76: 251–6

    Article  PubMed  CAS  Google Scholar 

  76. Vetter U, Pontz B, Zauner E, et al. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int 1992; 50: 36–41

    Article  PubMed  CAS  Google Scholar 

  77. Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975; 7: 488–91

    Article  PubMed  CAS  Google Scholar 

  78. Marini JC, Hopkins E, Reing CM, et al. Growth hormone treatment trial of children with types III and IV osteogenesis imperfecta. Sixth International Conference on Osteogenesis Imperfecta. 1996 Sep 19–21; Utrecht, The Netherlands

  79. Sillence D, Briody J, Ault J, et al. Factors which influence the efficacy of growth hormone in 15 children with osteogenesis imperfecta types I and IV. Sixth International Conference on Osteogenesis Imperfecta. 1996 Sep 19–21; Utrecht, The Netherlands

  80. Antoniazzi F, Bertoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996; 129: 432–9

    Article  PubMed  CAS  Google Scholar 

  81. Antoniazzi F. Therapeutic approach with growth hormone. 7th International Conference on Osteogenesis Imperfecta. 1999 Aug 29–Sep 1; Montreal, Canada

  82. Kodama H, Kubota K, Abe T. Osteogenesis imperfecta: are fractures and growth hormone treatment linked? J Pediatr 1998; 132: 559–60

    PubMed  CAS  Google Scholar 

  83. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80–100

    Article  PubMed  CAS  Google Scholar 

  84. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266–83

    Article  CAS  Google Scholar 

  85. Allgrove J. Biphosphonates. Arch Dis Child 1997; 76: 73–5

    Article  PubMed  CAS  Google Scholar 

  86. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf 1996; 14: 158–70

    Article  PubMed  CAS  Google Scholar 

  87. Devogelaer JP, Malghem J, Maldague B, et al. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987; 16: 360–3

    Article  PubMed  CAS  Google Scholar 

  88. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta? J Pediatr Orthop 1988; 8: 71–2

    Article  PubMed  CAS  Google Scholar 

  89. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, et al. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997; 156: 792–4

    Article  PubMed  CAS  Google Scholar 

  90. Williams CJ, Smith RA, Ball RJ, et al. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. Arch Dis Child 1997; 76: 169–70

    Article  PubMed  CAS  Google Scholar 

  91. Shaw NJ. Bisphosphonates in osteogenesis imperfecta. Arch Dis Child 1997; 77: 92–3

    PubMed  CAS  Google Scholar 

  92. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622–5

    Article  PubMed  CAS  Google Scholar 

  93. Fujiwara I, Ogawa E, Igarashi Y, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998; 157: 261–2

    PubMed  CAS  Google Scholar 

  94. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64–8

    Article  PubMed  CAS  Google Scholar 

  95. Glorieux FH, Bishop NJ, Plofkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947–52

    Article  PubMed  CAS  Google Scholar 

  96. Plofkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846–50

    Article  Google Scholar 

  97. Fracassi E, Gatti D, Antoniazzi F, et al. Cyclic administration of intravenous neridronate in patients with osteogenesis imperfecta. 7th International Conference on Osteogenesis Imperfecta. 1999 Aug 29–Sep 1; Montreal, Canada

  98. Marini JC, Gerber NL. Osteogenesis imperfecta. Rehabilitation and prospects for gene therapy. JAMA 1997; 277: 746–50

    Article  PubMed  CAS  Google Scholar 

  99. Prockop DJ. What holds us together? Why do some of us fall apart? What can we do about it? Matrix Biol 1998; 16: 519–28

    Article  PubMed  CAS  Google Scholar 

  100. Pereira RF, O’Hara MD, Laptev AV, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1998; 95: 1142–7

    Article  PubMed  CAS  Google Scholar 

  101. Marini JC. Osteogenesis imperfecta calls for caution [letter]. Nat Med 1999; 5: 466–7

    Article  PubMed  CAS  Google Scholar 

  102. Bishop NJ. Osteogenesis imperfecta calls for caution [letter]. Nat Med 1999; 5: 466–7

    Article  PubMed  CAS  Google Scholar 

  103. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 1995; 64: 403–34

    Article  PubMed  CAS  Google Scholar 

  104. Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest 1996; 97: 448–54

    Article  PubMed  CAS  Google Scholar 

  105. Grassi G, Forlino A, Marini JC. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects. Nucleic Acids Res 1997; 25: 3451–8

    Article  PubMed  CAS  Google Scholar 

  106. Dawson PA, Forlino A, Marini JC. Allele specific cleavage of murine mutant type I collagen RNA using hammerhead ribozymes in vitro: development of gene therapy for osteogenesis imperfecta. Am J Hum Genet 1998; Suppl. 63: A398

    Google Scholar 

Download references

Acknowledgements

The authors wish to thank the Italian Association for Osteogenesis Imperfecta (As.It.O.I.) for their encouragement and support in research in OI, and Mrs E.R. Smith for the correction of the manuscript.

Author information

Authors and Affiliations

  1. Dipartimento Materno-Infantile e di Biologia-Genetica, Università degli Studi di Verona, Verona, Italy

    Franco Antoniazzi, Monica Mottes & Luciano Tatò

  2. I.R.C.C.S. ‘E. Medea’, Associazione La Nostra Famiglia, Bosisio Parini (LC), Italy

    Paolo Fraschini

  3. Divisione di Ortopedia Pediatrica, Spedali Civili, Brescia, Italy

    Pier Carlo Brunelli

Authors
  1. Franco Antoniazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica Mottes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Fraschini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pier Carlo Brunelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luciano Tatò
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Franco Antoniazzi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antoniazzi, F., Mottes, M., Fraschini, P. et al. Osteogenesis Imperfecta. Paediatr Drugs 2, 465–488 (2000). https://doi.org/10.2165/00128072-200002060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200002060-00005

Keywords

Search

Navigation